Pathstone Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

Pathstone Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-88,388	Closed	-$431K	–	2358
2025 Q3	$431K	Sell	88,388 -16,004	-15%	-$84K	﹤0.01%	1838
2025 Q2	$528K	Sell	104,392 -107,596	-51%	-$529K	﹤0.01%	1701
2025 Q1	$1.12M	Buy	211,988 +166,763	+369%	+$1.22M	﹤0.01%	1322
2024 Q4	$306K	Sell	45,225 -4,153	-8%	-$27.9K	﹤0.01%	1960
2024 Q3	$325K	Buy	49,378 +1,417	+3%	+$10.2K	﹤0.01%	1935
2024 Q2	$360K	Buy	47,961 +676	+1%	+$5.9K	﹤0.01%	1863
2024 Q1	$471K	Buy	47,285 +1,258	+3%	+$14K	﹤0.01%	1709
2023 Q4	$454K	Buy	+46,027	New	+$328K	﹤0.01%	1568

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Pathstone Holdings's RXRX Position: Q4 2025 in Review

Pathstone Holdings sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 88,388 shares — an estimated $431K sold.

Pathstone Holdings first reported a position in RXRX in Q4 2023 and held it in 8 quarters. The position peaked at $1.12M in Q1 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Pathstone Holdings reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Pathstone Holdings sold 88,388 Recursion Pharmaceuticals shares in Q4 2025, an estimated $431K.
Pathstone Holdings first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Pathstone Holdings's Recursion Pharmaceuticals position peaked at $1.12M in Q1 2025.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Pathstone Holdings's 13F filing for Q4 2025, filed 13 Feb 2026.